SELLAS Life Sciences Completes Enrollment And Reports Positive Initial Data From Phase 2a Trial Of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences has completed enrollment and reported positive initial data from its Phase 2a trial of SLS009 in relapsed/refractory acute myeloid leukemia. The trial showed promising response rates and overall survival improvements, particularly in patients with specific genetic mutations.
June 10, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SELLAS Life Sciences has completed enrollment and reported positive initial data from its Phase 2a trial of SLS009 in relapsed/refractory acute myeloid leukemia. The trial showed promising response rates and overall survival improvements, particularly in patients with specific genetic mutations.
The positive initial data from the Phase 2a trial of SLS009, including high response rates and improved overall survival, is likely to boost investor confidence in SELLAS Life Sciences. This could lead to a short-term increase in the stock price as the market reacts to the promising clinical trial results.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100